JP2021167346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021167346A5 JP2021167346A5 JP2021118771A JP2021118771A JP2021167346A5 JP 2021167346 A5 JP2021167346 A5 JP 2021167346A5 JP 2021118771 A JP2021118771 A JP 2021118771A JP 2021118771 A JP2021118771 A JP 2021118771A JP 2021167346 A5 JP2021167346 A5 JP 2021167346A5
- Authority
- JP
- Japan
- Prior art keywords
- mass
- ethynyl
- pyrazolo
- dimethoxyphenyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 17
- -1 4-amino-3-((3,5-dimethoxyphenyl) ethynyl) -1H-pyrazolo [3,4-d] pyrimidin-1-yl Chemical group 0.000 claims description 14
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 229950008138 carmellose Drugs 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- 229960000913 crospovidone Drugs 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims 5
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- 238000010828 elution Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- KEIPNCCJPRMIAX-HNNXBMFYSA-N 1-[(3s)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC(C#CC=2C3=C(N)N=CN=C3N([C@@H]3CN(CC3)C(=O)C=C)N=2)=C1 KEIPNCCJPRMIAX-HNNXBMFYSA-N 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018051620 | 2018-03-19 | ||
| JP2018051620 | 2018-03-19 | ||
| JP2020507802A JP6918204B2 (ja) | 2018-03-19 | 2019-03-18 | アルキル硫酸ナトリウムを含む医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507802A Division JP6918204B2 (ja) | 2018-03-19 | 2019-03-18 | アルキル硫酸ナトリウムを含む医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021167346A JP2021167346A (ja) | 2021-10-21 |
| JP2021167346A5 true JP2021167346A5 (enExample) | 2022-03-16 |
| JP7322103B2 JP7322103B2 (ja) | 2023-08-07 |
Family
ID=67987327
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507802A Active JP6918204B2 (ja) | 2018-03-19 | 2019-03-18 | アルキル硫酸ナトリウムを含む医薬組成物 |
| JP2021118771A Active JP7322103B2 (ja) | 2018-03-19 | 2021-07-19 | アルキル硫酸ナトリウムを含む医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507802A Active JP6918204B2 (ja) | 2018-03-19 | 2019-03-18 | アルキル硫酸ナトリウムを含む医薬組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11833151B2 (enExample) |
| EP (3) | EP4353222A1 (enExample) |
| JP (2) | JP6918204B2 (enExample) |
| KR (1) | KR102473372B1 (enExample) |
| CN (1) | CN111867594A (enExample) |
| AU (1) | AU2019239404B2 (enExample) |
| CA (1) | CA3094431C (enExample) |
| DK (1) | DK3769765T3 (enExample) |
| ES (1) | ES2980333T3 (enExample) |
| FI (1) | FI3769765T3 (enExample) |
| HU (1) | HUE067430T2 (enExample) |
| MA (1) | MA52093A (enExample) |
| MX (1) | MX2020009762A (enExample) |
| MY (1) | MY203305A (enExample) |
| PH (1) | PH12020551412A1 (enExample) |
| PL (1) | PL3769765T3 (enExample) |
| PT (1) | PT3769765T (enExample) |
| RU (1) | RU2759746C1 (enExample) |
| SG (1) | SG11202008435SA (enExample) |
| TW (1) | TWI790364B (enExample) |
| WO (1) | WO2019181876A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250007056A (ko) * | 2016-03-04 | 2025-01-13 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| US11833151B2 (en) * | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
| US20220023300A1 (en) * | 2018-11-26 | 2022-01-27 | Taiho Pharmaceutical Co., Ltd. | Therapeutic and prophylactic method for tumor treatable with endocrine therapy by combined use of fibroblast growth factor receptor inhibitor with endocrine therapy |
| JP2024509472A (ja) * | 2021-03-08 | 2024-03-01 | 大鵬薬品工業株式会社 | Ｆｇｆｒ２及び癌ドライバー遺伝子に遺伝子変化が同時発生する患者におけるがんの治療 |
| WO2023238929A1 (ja) * | 2022-06-10 | 2023-12-14 | 大鵬薬品工業株式会社 | ピミテスピブを含有する医薬組成物 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3433239A1 (de) * | 1984-09-11 | 1986-03-20 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung |
| FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
| JP4117811B2 (ja) * | 1997-04-22 | 2008-07-16 | 日本化薬株式会社 | フルタミド製剤及びその製法 |
| AU6853498A (en) * | 1997-04-22 | 1998-11-13 | Nippon Kayaku Kabushiki Kaisha | Flutamide preparations and method for manufacturing the same |
| NZ328751A (en) * | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| KR101190912B1 (ko) | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법 |
| DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| KR100883289B1 (ko) | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물 |
| ES2444866T3 (es) | 2004-10-20 | 2014-02-27 | Merck Serono Sa | Derivados de 3-arilamino piridina |
| CA2611030A1 (en) * | 2005-06-17 | 2006-12-21 | Pfizer Inc. | Alpha-(aryl-or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl1-receptor antagonists |
| MX2008002114A (es) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
| PE20070543A1 (es) | 2005-10-06 | 2007-06-14 | Schering Corp | Pirazolopirimidinas como inhibidores de protein quinasas |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| DE602006021645D1 (de) | 2005-11-15 | 2011-06-09 | Array Biopharma Inc | Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten |
| EP1981890A2 (en) | 2006-01-25 | 2008-10-22 | OSI Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
| ES2396051T3 (es) * | 2006-04-26 | 2013-02-18 | Supernus Pharmaceuticals, Inc. | Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal |
| EP1939197A1 (en) | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | 8-ethinylxanthine derivatives as selective A2A receptor antagonists |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| EP2139487B1 (en) | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| PT2139484E (pt) | 2007-04-10 | 2013-10-31 | Exelixis Inc | Métodos de tratamento de cancro usando inibidores piridopirimidinona de pi3k-alfa |
| US9241908B2 (en) * | 2007-10-16 | 2016-01-26 | Biocon Limited | Orally administrable solid pharmaceutical composition and a process thereof |
| CA2728063A1 (en) | 2008-06-19 | 2009-12-23 | Astrazeneca Ab | Pyrazole compounds 436 |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB0819105D0 (en) | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
| ES2458872T3 (es) | 2009-04-30 | 2014-05-07 | Novartis Ag | Derivados de imidazol y su uso como moduladores de quinasas dependientes de ciclina |
| KR101483215B1 (ko) | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| US9140689B2 (en) | 2010-03-14 | 2015-09-22 | Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
| JP5783499B2 (ja) * | 2010-03-29 | 2015-09-24 | 味の素株式会社 | フェニルアラニン誘導体を含有する医薬製剤 |
| DE102011015188A1 (de) | 2010-03-29 | 2011-09-29 | Herbert Kannegiesser Gmbh | Verfahren zur Nassbehandlung, insbesondere zum Reinigen, von Gegenständen |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| CN103459400B (zh) | 2011-04-06 | 2016-05-18 | 大鹏药品工业株式会社 | 咪唑并噁嗪化合物或其盐 |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| AU2013210403B2 (en) | 2012-01-19 | 2016-01-14 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| MX2014009303A (es) | 2012-01-31 | 2014-10-14 | Novartis Ag | Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer. |
| CA2865021C (en) | 2012-02-23 | 2020-06-30 | Bayer Intellectual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
| WO2014007217A1 (ja) | 2012-07-02 | 2014-01-09 | 大鵬薬品工業株式会社 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| BR112015012051A2 (pt) | 2012-11-26 | 2017-12-12 | Roche Innovation Ct Copenhagen As | composições e métodos para modulação de expressão de fgfr3 |
| JP2016510751A (ja) | 2013-03-06 | 2016-04-11 | ジェネンテック， インコーポレイテッド | 抗がん剤耐性を治療及び予防する方法 |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| JP6289459B2 (ja) | 2013-06-20 | 2018-03-07 | 大鵬薬品工業株式会社 | ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法 |
| JP6084292B2 (ja) | 2013-07-18 | 2017-02-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤耐性癌の治療薬 |
| DK3023100T3 (da) | 2013-07-18 | 2019-05-27 | Taiho Pharmaceutical Co Ltd | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer |
| WO2015150900A2 (en) * | 2014-03-31 | 2015-10-08 | Debiopharm International Sa | Fgfr fusions |
| WO2015163448A1 (ja) | 2014-04-25 | 2015-10-29 | 中外製薬株式会社 | ４環性化合物を高用量含有する製剤 |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| US10481946B2 (en) * | 2014-05-12 | 2019-11-19 | Hitachi, Ltd. | Information-processing device, processing method thereof, and input/output device |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| MA41350A (fr) | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| CN105859721B (zh) | 2015-01-22 | 2018-04-17 | 浙江京新药业股份有限公司 | 一种伊布鲁替尼的制备方法 |
| CN107250108B (zh) | 2015-02-05 | 2020-11-27 | 特尔诺沃有限公司 | 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合 |
| WO2016130917A1 (en) | 2015-02-12 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Synergistic cancer treatment |
| CN107428779A (zh) | 2015-02-27 | 2017-12-01 | 大鹏药品工业株式会社 | 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法 |
| US10434103B2 (en) | 2015-03-31 | 2019-10-08 | Taiho Pharmaceutical Co., Ltd. | Crystal of 3,5-disubstituted benzene alkynyl compound |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| EA201890161A1 (ru) | 2015-06-29 | 2018-06-29 | Верастэм, Инк. | Терапевтические композиции, комбинации и способы применения |
| EP3120851A1 (en) | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| BR112018001438A2 (en) * | 2015-07-24 | 2018-12-04 | Debiopharm International S.A. | gffr expression and susceptibility to a gffr inhibitor |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| WO2017086332A1 (ja) | 2015-11-19 | 2017-05-26 | 国立大学法人金沢大学 | 間葉系ｋｒａｓ変異型がん治療剤 |
| KR20250007056A (ko) * | 2016-03-04 | 2025-01-13 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| JP2018002662A (ja) | 2016-07-01 | 2018-01-11 | 大鵬薬品工業株式会社 | キノリルピロロピリミジル縮合環化合物を合成するために有用な中間体 |
| JP6296308B1 (ja) | 2016-09-26 | 2018-03-20 | ツジカワ株式会社 | ロール装置 |
| CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| US11833151B2 (en) * | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
| JP7161546B2 (ja) | 2018-11-09 | 2022-10-26 | 大鵬薬品工業株式会社 | ジメトキシベンゼン化合物の類縁物質、該化合物の分析方法及び標準品 |
| AU2018448845B2 (en) | 2018-11-09 | 2022-03-24 | Taiho Pharmaceutical Co., Ltd. | Method for producing dimethoxybenzene compound |
| US20220023300A1 (en) | 2018-11-26 | 2022-01-27 | Taiho Pharmaceutical Co., Ltd. | Therapeutic and prophylactic method for tumor treatable with endocrine therapy by combined use of fibroblast growth factor receptor inhibitor with endocrine therapy |
| WO2020170355A1 (ja) | 2019-02-20 | 2020-08-27 | 大鵬薬品工業株式会社 | Ｆｇｆｒ１変異腫瘍の治療方法 |
| EP3932425A4 (en) | 2019-02-28 | 2022-12-07 | Taiho Pharmaceutical Co., Ltd. | CANCER THERAPY WITH 3,5-DISUBSTITUTED BENZENE ALKINYL COMPOUND AND IMMUNE CHECKPOINT INHIBITOR |
| JP7574184B2 (ja) | 2019-06-21 | 2024-10-28 | 大鵬薬品工業株式会社 | 悪性腫瘍の治療方法 |
-
2019
- 2019-03-18 US US16/982,377 patent/US11833151B2/en active Active
- 2019-03-18 ES ES19771998T patent/ES2980333T3/es active Active
- 2019-03-18 MA MA052093A patent/MA52093A/fr unknown
- 2019-03-18 EP EP24160537.7A patent/EP4353222A1/en not_active Withdrawn
- 2019-03-18 RU RU2020133810A patent/RU2759746C1/ru active
- 2019-03-18 CN CN201980020022.5A patent/CN111867594A/zh active Pending
- 2019-03-18 MY MYPI2020004844A patent/MY203305A/en unknown
- 2019-03-18 TW TW108109195A patent/TWI790364B/zh active
- 2019-03-18 FI FIEP19771998.2T patent/FI3769765T3/fi active
- 2019-03-18 SG SG11202008435SA patent/SG11202008435SA/en unknown
- 2019-03-18 DK DK19771998.2T patent/DK3769765T3/da active
- 2019-03-18 PT PT197719982T patent/PT3769765T/pt unknown
- 2019-03-18 HU HUE19771998A patent/HUE067430T2/hu unknown
- 2019-03-18 EP EP24207166.0A patent/EP4470621A3/en not_active Withdrawn
- 2019-03-18 PL PL19771998.2T patent/PL3769765T3/pl unknown
- 2019-03-18 MX MX2020009762A patent/MX2020009762A/es unknown
- 2019-03-18 WO PCT/JP2019/011251 patent/WO2019181876A1/ja not_active Ceased
- 2019-03-18 JP JP2020507802A patent/JP6918204B2/ja active Active
- 2019-03-18 KR KR1020207029418A patent/KR102473372B1/ko active Active
- 2019-03-18 EP EP19771998.2A patent/EP3769765B1/en active Active
- 2019-03-18 AU AU2019239404A patent/AU2019239404B2/en active Active
- 2019-03-18 CA CA3094431A patent/CA3094431C/en active Active
-
2020
- 2020-09-09 PH PH12020551412A patent/PH12020551412A1/en unknown
-
2021
- 2021-07-19 JP JP2021118771A patent/JP7322103B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6936274B2 (en) | Storage stable thyroxine active drug formulations and methods for their production | |
| JP4816828B2 (ja) | ソリフェナシン非晶質体を含有した固形医薬組成物 | |
| TW201609091A (zh) | 用於口服投藥之包含依澤替米貝（ｅｚｅｔｉｍｉｂｅ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）的複合調配物 | |
| EP4331607B1 (en) | Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide | |
| JP2007091633A (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
| JP5628910B2 (ja) | ６−（５−クロロ−２−ピリジル）−５−［（４−メチル−１−ピペラジニル）カルボニルオキシ］−７−オキソ−６，７−ジヒドロ−５ｈ−ピロロ［３，４−ｂ］ピラジンの配合物 | |
| EP2435052B1 (en) | Solid oral dosage forms of lamivudine with isomalt | |
| FI3769765T3 (fi) | Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus | |
| KR20170061616A (ko) | 피마살탄의 신규 염 | |
| RU2401109C2 (ru) | Таблетированный препарат с замедленным высвобождением для вертиго | |
| CN111670189A (zh) | 对rsv具有活性的环烷基取代的吡唑并嘧啶 | |
| WO2008085674A1 (en) | Pharmaceutical compositions comprising celecoxib co-crystals | |
| JP2017210422A (ja) | 医薬組成物、医薬組成物の製造方法、及び非晶質体の安定性を向上させる方法 | |
| JPWO2001089573A1 (ja) | 製剤の安定化方法 | |
| JP2008509914A5 (enExample) | ||
| JP4473539B2 (ja) | 医薬組成物 | |
| JPH03120211A (ja) | 粒状カルニチン製剤 | |
| JP2024524933A5 (enExample) | ||
| JP2024055713A (ja) | ビラスチン錠剤およびその製造方法 | |
| JP2024501640A (ja) | フェドラチニブの投薬 | |
| JP2018095567A (ja) | ４−アミノ−３−ブタン酸類縁体含有固形製剤 | |
| JP6565334B2 (ja) | 固形製剤 | |
| JP7049610B2 (ja) | レボセチリジン固形製剤 | |
| JP2018203705A (ja) | レボセチリジン固形製剤 | |
| CN110300758A (zh) | (s)-2-[[[(r)-2-(6-氨基嘌呤-9-基)-1-甲基-乙氧基]甲基-苯氧基-磷酰基]氨基]-丙酸环丁酯及其生产和使用方法 |